Hospital Universitario Fundacion Alcorcon

Research site

Spain Calle Budapest 1, 28922 Alcorcon, Spain

31 trials recruiting
Asthma · Parkinson's disease · Immune thrombocytopenia
Adults and children

About Specializations

Hospital Universitario Fundacion Alcorcon in Alcorcon, Spain specialises in clinical trials of conditions such as Asthma, Parkinson's disease, Immune thrombocytopenia, Major depression, and other specialisations. This site conducts important research.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Calle Budapest 128922 AlcorconSpain

Open in maps ↗

Recruiting now: 31 trials
Conditions studied: 58

More sites in Alcorcon Spain

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

67 clinical trials

Chronic spontaneous urticaria

Recruiting

A study to evaluate the effectiveness and safety of ritlecitinib tosilate and loratadine in adults with chronic spontaneous urticaria (hives)

Registered drug

A study to evaluate the effectiveness and safety of ritlecitinib tosilate and loratadine in adults with chronic spontaneous urticaria (hives)

Registered drug

Spain

Participants:18–64 years · 65+ years
Substances:Loratadine
Sponsor:Pfizer Inc.

Contact Research Centre

COVID-19

Recruiting

A study testing molnupiravir in adults with COVID-19 who are not hospitalized and are at high risk for serious illness

Investigational

A study testing molnupiravir in adults with COVID-19 who are not hospitalized and are at high risk for serious illness

Investigational

Spain

Participants:18–64 years · 65+ years
Substances:Molnupiravir
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Vitiligo

Recruiting

Study of ruxolitinib cream for children aged 6 to 12 years with non-segmental vitiligo

Investigational

Study of ruxolitinib cream for children aged 6 to 12 years with non-segmental vitiligo

Investigational

Spain

Participants:0–17 years
Substances:Ruxolitinib
Sponsor:Incyte Corp.

Contact Research Centre

Bladder transitional cell carcinoma

Recruiting

Study of nadofaragene firadenovec alone or with gemcitabine, docetaxel or pembrolizumab in adults with non-muscle invasive bladder cancer who did not respond to BCG therapy

Registered drugNo placebo

Study of nadofaragene firadenovec alone or with gemcitabine, docetaxel or pembrolizumab in adults with non-muscle invasive bladder cancer who did not respond to BCG therapy

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Docetaxel
Sponsor:Ferring Pharmaceuticals A/S

Contact Research Centre

Vitiligo+2

Recruiting

Long-term safety study of oral povorcitinib in patients with hidradenitis suppurativa, prurigo nodularis, or vitiligo who previously participated in clinical trials

InvestigationalNo placebo

Long-term safety study of oral povorcitinib in patients with hidradenitis suppurativa, prurigo nodularis, or vitiligo who previously participated in clinical trials

InvestigationalNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Povorcitinib
Sponsor:Incyte Corp.

Contact Research Centre

Bladder transitional cell carcinoma

Recruiting

Study of Nadofaragene Firadenovec for Adults with Intermediate Risk Non-Muscle Invasive Bladder Cancer

InvestigationalNo placebo

Study of Nadofaragene Firadenovec for Adults with Intermediate Risk Non-Muscle Invasive Bladder Cancer

InvestigationalNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Nadofaragene firadenovec
Sponsor:Ferring Pharmaceuticals A/S

Contact Research Centre

Schizophrenia

Recruiting

Study on Vafidemstat for Treating Negative Symptoms and Cognitive Impairment in Adults with Schizophrenia

Investigational

Study on Vafidemstat for Treating Negative Symptoms and Cognitive Impairment in Adults with Schizophrenia

Investigational

Spain

Participants:18–64 years
Substances:Vafidemstat
Sponsor:Oryzon Genomics S.A.

Contact Research Centre

Asthma

Recruiting

Study of Beclometasone Dipropionate in Patients with Asthma to Evaluate Disease Characteristics and Control

Registered drugNo placebo

Study of Beclometasone Dipropionate in Patients with Asthma to Evaluate Disease Characteristics and Control

Registered drugNo placebo

Spain

Participants:0–17 years · 18–64 years · 65+ years
Substances:Beclometasone Dipropionate
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Asthma

Recruiting

Efficacy and Safety of Depemokimab for Early Intervention in Adults and Adolescents with Type 2 Asthma at Risk of Exacerbations

Registered drug

Efficacy and Safety of Depemokimab for Early Intervention in Adults and Adolescents with Type 2 Asthma at Risk of Exacerbations

Registered drug

Spain

Participants:0–17 years · 18–64 years · 65+ years
Substances:Depemokimab
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Metabolic dysfunction-associated steatohepatitis

Recruiting

A Phase 3 Study of Efimosfermin Alfa to Assess Safety and Tolerability in Adults with F2‑F3 Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)

Investigational

A Phase 3 Study of Efimosfermin Alfa to Assess Safety and Tolerability in Adults with F2‑F3 Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)

Investigational

Spain

Participants:18–64 years · 65+ years
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Metabolic dysfunction-associated steatohepatitis

Recruiting

Safety and Efficacy of Efimosfermin Alfa in Participants with Biopsy‑Confirmed F2‑ or F3‑Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)

Investigational

Safety and Efficacy of Efimosfermin Alfa in Participants with Biopsy‑Confirmed F2‑ or F3‑Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)

Investigational

Spain

Participants:18–64 years · 65+ years
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Cardiac failure+1

Recruiting

Study of Zenagamtide (NNC0487-0111) versus placebo in patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational

Study of Zenagamtide (NNC0487-0111) versus placebo in patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational

Spain

Participants:18–64 years · 65+ years
Sponsor:Novo Nordisk A/S

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites